COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Retrieved on:
Tuesday, September 14, 2021
Food, National Institute of Mental Health, Paper, US Foods, CEO, FDA, Mental health, University, Forward-looking statement, Intellectual property, Doctor of Philosophy, Patient, CMPS, Drug Quality and Security Act, Nasdaq, Private Securities Litigation Reform Act, Patent, Intention, COMPASS, Arboleas, U.S. Securities and Exchange Commission, Max Planck Institute for Social Anthropology, LinkedIn, Annual report, Terminology, TRD, IP, University of Basel, Review, Prodrug, Head, IIB, Securities Act of 1933, Max Planck Society, SEC, Research, Czech Republic, Social media, Goal, National Institute, File, Pharmaceutical industry, Medicinal plants, Risk management
The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.
Key Points:
- The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.
- The new substances include novel derivatives of known compounds, increasing the confidence in therapeutic effects and safety profile while offering optimised characteristics.
- Lars Wilde, Chief Business Officer, President and Co-founder, COMPASS Pathways, said: We are delighted to be working with Matthias and MiHKAL GmbH.
- This agreement will strengthen and expand our IP and development portfolio with new compounds.